LAVOMAKS

Active material: Tiloron
When ATH: J05AX
CCF: The antiviral and immunomodulatory drugs. Inducer of interferon synthesis
ICD-10 codes (testimony): A56.0, A56.1, A56.4, A60, B00, B01, B02, B15, B16, B17.1, B18.1, B18.2, B25, G04, G35, J06.9, J10, J16.0
When CSF: 09.01.05.02
Manufacturer: NIZHFARM of (Russia)

Pharmaceutical form, composition and packaging

◊ Pills, coated from yellow to orange, round; in cross section showed two layers; orange tablet core.

Excipients: magnesium hydroxycarbonate hydrate, povidone (low molecular weight polyvinyl Medical), calcium stearate, colloidal silicon dioxide (aэrosyl), beeswax, Oil vaseline, sucrose, talc, About tropeolin, Titanium dioxide, high molecular weight polyethylene glycol 6000 (to give tablets weighing 0.39 g).

6 PC. – packings Valium planimetric (1) – packs cardboard.
10 PC. – packings Valium planimetric (1) – packs cardboard.

Pharmacological action

The antiviral and immunomodulatory drugs. Lavomax stimulates the body's α-, beta-, c-интерферонов. In response to the interferon produced Lavomax, mainly, epithelial cells of the intestine, gepatocitami, T-lymphocytes and neutrophils.

After taking the drug inside a maximum production of interferon is defined in the sequence gut-liver-blood through 4-24 no. Lavomax has immunomodulatory and antiviral action. It stimulates bone marrow stem cells, dose-dependent increases antibody, reduces the degree of immunosuppression, restores ratio T-helper / T-suppressor.

It is effective against a variety of viral infections, incl. against influenza viruses, other acute respiratory viral infections, hepatitis viruses and herpes. The mechanism of antiviral action due to inhibition of translation of virus-specific proteins in infected cells, as a result, it suppresses reproduction of viruses.

Pharmacokinetics

Absorption

After taking the drug inside tilorona is rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%.

Distribution

The binding to plasma proteins – about 80%.

Metabolism and excretion

Tilorona no biotransformation and accumulates in the body. Displayed virtually unchanged in the feces (about 70%) and urine (about 9%). T_1/2 is 48 no.

Testimony

The drug is used in adults.

- Flu and SARS (Prevention and treatment);

- Viral hepatitis A, And C;

- Herpes infection;

- Cytomegalovirus infection;

- In the complex treatment of allergic and infectious viral encephalomyelitis (multiple sclerosis, leykoentsefality, uveoéncefality);

- In the complex treatment of urogenital and respiratory chlamydia.

Dosage regimen

To prevention of influenza and SARS Lavomax prescribe a dose 125 mg 1 once a week for 6 weeks.

To treatment of influenza and other acute respiratory viral infections first 2 day illness appoint 125 mg / day, then 125 mg after 48 no. Kursovaya dose – 750 mg (6 tab.).

For nonspecific prevention of hepatitis A the drug is prescribed in a dose 125 mg per week for 6 weeks.

At the treatment of viral hepatitis A dose on the first day is for 125 mg 2 times / day, then – by 125 mg after 48 no. A course of treatment – 1.25 g (10 tab.).

At treatment of acute hepatitis B the first and second days – by 125 mg / day, then – by 125 mg after 48 no. A course of treatment – 2 g (16 tab.).

At protracted course of hepatitis B first day – by 125 mg 2 times / day, then – by 125 mg after 48 no. A course of treatment – 2.5 g (20 tab.).

At chronic hepatitis B in the initial phase of treatment (2.5 g – 20 tab.) first 2 day – by 250 mg, then 125 mg after 48 no. In the continuation phase (from 1.25 g – 10 tab. to 2.5 g – 20 tab.) – by 125 mg per week. Heading dose varies from Lavomax 3.75 g to 5 g, the duration of treatment is 3.5-6 months depending on the results of biochemical, immunological and morphological studies, reflecting the degree of activity of the process.

At Acute hepatitis C the first and second days of treatment prescribed by 125 mg, then – by 125 mg after 48 no. A course of treatment – 2.5 g (20 tab.).

At chronic hepatitis C in the initial phase of treatment (2.5 g – 20 tab.) first 2 day – by 250 mg / day, then – 125 mg after 48 no. In the continuation phase (2.5 g – 20 tab.) appoint 125 mg in the Sun. Kursovaya dose Lavomax – 5 g, the duration of treatment is 6 months depending on the results of biochemical, immunological and morphological studies, reflecting the degree of activity of the process.

To Treatment of herpes, cytomegalovirus infection the first dose 2 days of 125 mg, then take the 125 mg after 48 no. Kursovaya dose – 2.5 g.

At urogenital and respiratory chlamydia Lavomax in the first two days prescribed in doses 125 mg / day, then – by 125 mg after 48 no. Kursovaya dose – 1.25 g (10 tab.).

IN complex therapy of infections neyrovirusnyh Dose set individually, duration of the course – 4 of the week.

The drug is taken orally after a meal.

Side effect

From the digestive system: in some cases – dyspeptic symptoms.

Other: possible short-term fever, allergic reactions

Contraindications

- Pregnancy;

- Lactation (breast-feeding);

- Children up to age 7 years;

- Hypersensitivity to the drug.

Pregnancy and lactation

Lavomax is contraindicated during pregnancy and lactation (breast-feeding).

Cautions

Lavomax compatible with antibiotics and traditional means of treatment of viral and bacterial infections.

Overdose

So far, cases of drug overdose were reported Lavomax.

Drug Interactions

Clinically significant drug interactions Lavomax with antibiotics and traditional means of treatment of viral and bacterial infections have been identified.

Conditions of supply of pharmacies

The drug is resolved to application as an agent Valium holidays.

Conditions and terms

List B. The drug should be stored out of reach of children, dry, dark place at a temperature no higher than 25 ° C. Shelf life – 2 year.